

EMAGEON INC
Form 4
December 10, 2008

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *
ACCIPITER CAPITAL MANAGEMENT, LLC

(Last) (First) (Middle)

666 5TH AVENUE, 35TH FLOOR

(Street)

NEW YORK, NY 10103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
EMAGEON INC [EMAG]

3. Date of Earliest Transaction (Month/Day/Year)
12/08/2008

4. If Amendment, Date Original Filed (Month/Day/Year)

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

___ Director ___X___ 10% Owner
___ Officer (give title below) ___ Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)
___ Form filed by One Reporting Person
X Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	V	Amount	(A) or (D)	Price			
Common Stock, \$0.001 Par Value	12/08/2008		P		10,232	A	\$ 2.5057	1,130,885	I	By ALSF (Offshore), Ltd. ⁽¹⁾
Common Stock, \$0.001 Par Value	12/09/2008		P		3,904	A	\$ 2.5125	1,134,789	I	By ALSF (Offshore), Ltd. ⁽¹⁾
Common Stock, \$0.001 Par Value	12/08/2008		P		9,968	A	\$ 2.5057	1,089,988	I	By ALSF, LP ⁽²⁾

Edgar Filing: EMAGEON INC - Form 4

Common Stock, \$0.001 Par Value	12/09/2008	P	8,996	A	\$ 2.5125	1,098,984	I	By ALSF, LP ⁽²⁾
Common Stock, \$0.001 Par Value						662,924	I	By ALSF II (Offshore), Ltd. ⁽³⁾
Common Stock, \$0.001 Par Value						391,076	I	By ALSF II (QP), LP ⁽⁴⁾
Common Stock, \$0.001 Par Value						295,566	I	By ALSF II, LP ⁽⁵⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secur Bene Own Follo Repor Trans (Instr
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

ACCIPITER CAPITAL MANAGEMENT, LLC
666 5TH AVENUE

X

35TH FLOOR
NEW YORK, NY 10103

ACCIPITER LIFE SCIENCES FUND II L P
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

Accipiter Life Sciences Fund II Offshore Ltd
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

ACCIPITER LIFE SCIENCES FUND II QP L P
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

ACCIPITER LIFE SCIENCES FUND LP
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

ACCIPITER LIFE SCIENCES FUND OFFSHORE LTD
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

Candens Capital LLC
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

HOFFMAN GABE
666 5TH AVENUE
35TH FLOOR
NEW YORK, NY 10103

X

Signatures

By: Accipiter Capital Management, LLC; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

By: Accipiter Life Sciences Fund II, LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

By: Accipiter Life Sciences Fund II (Offshore), Ltd.; By: Accipiter Capital Management, LLC, its Investment Manager; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

By: Accipiter Life Sciences Fund II (QP), LP; By: Candens Capital, LLC, its General Partner; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

12/10/2008

Edgar Filing: EMAGEON INC - Form 4

By: Accipiter Life Sciences Fund, LP; By: Candens Capital, LLC, its General Partner; By: /s/
Gabe Hoffman, Managing Member

__Signature of Reporting Person

Date

By: Accipiter Life Sciences Fund (Offshore), Ltd.; By: Accipiter Capital Management, LLC,
its Investment Manager; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

By: Candens Capital, LLC; By: /s/ Gabe Hoffman, Managing Member

12/10/2008

__Signature of Reporting Person

Date

/s/ Hoffman, Gabe

12/10/2008

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Held by Accipiter Life Sciences Fund (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life Sciences Fund (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

(1) Held by Accipiter Life Sciences Fund, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund, LP and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

(2) Held by Accipiter Life Sciences Fund II (Offshore), Ltd. Accipiter Capital Management, LLC, the investment manager of Accipiter Life Sciences Fund II (Offshore), Ltd. and Gabe Hoffman, the managing member of Accipiter Capital Management, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

(3) Held by Accipiter Life Sciences Fund II (QP), LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II (QP), LP, and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

(4) Held by Accipiter Life Sciences Fund II, LP. Candens Capital, LLC, the general partner of Accipiter Life Sciences Fund II, LP and Gabe Hoffman, the managing member of Candens Capital, LLC, disclaim beneficial ownership of these securities except to the extent of their pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.